Sarepta Therapeutics (SRPT): "They Should Be Prosecuted," Says Jim Cramer

We recently published 12 Stocks Jim Cramer Discussed As Analyzed Morgan Stanley’s Comments. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is one of the stocks Jim Cramer recently discussed.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is a biotechnology company that focuses on gene-based therapies. It is one of the most controversial stocks right now due to a massive 40% share price drop in July. Sarepta Therapeutics, Inc. (NASDAQ:SRPT)’s stock was crushed after the FDA demanded that the firm stop shipments of its muscular dystrophy treatment due to patient deaths. Cramer wholeheartedly agreed with the FDA:

“[On firm announcing to not comply with the FDA request to stop shipping] Okay, if RFK Jr. agrees with that I guess they don’t need to. I mean this is part of the new government. And the new government, some people would say, is not in keeping what keeping the government of Hamilton and Jefferson, the founding fathers. And I would come back and say, they too have become irrelevant right now. They could be relevant later on but I’m not auditioning for the show of Hamilton here.

“Look they should be prosecuted if they go after them. Because they kill people. And historically, the FDA is a very good institution. . .our FDA’s the best in the world. They may think it’s not, I know it is. . .And that’s it. You know if you kill people with the trial, that drug is stopped. And last I looked, I would prosecute anyone, any company uses that, I would prosecute the CEO for homicide. Why don’t you just say, listen, I’m going against a charge of homicide because you’re killing people with that. The FDA wants to prove, this is a horrible disease, and the FDA would like, wanted, when this was approved to say, alright, we’ll do anything, these people have nothing. There’s no hope. So we’ll do this. But you can’t kill people on a trial. That’s the FDA’s rule. It’s not like Jim Cramer says, that’s the history of the FDA!”

While we acknowledge the potential of SRPT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.